title: Mechanisms of flushing due to niacin and abolition of these effects.
abstract: There are many factors that increase the risk of cardiovascular disease, and a prominent factor among these is dyslipidemia. The following literature review focuses on the use of niacin therapy in order to treat dyslipidemia and how to control the associated "niacin flush." The associated studies gathered are reviews and randomized control trials. They were obtained by using electronic searches. Certain keywords took precedence, and articles focusing on niacin therapy were chosen. Recent research has found promising insight into more effective prevention of the niacin-mediated flush through a selective antagonist for the prostaglandin D2 receptor, laropiprant. Aspirin (or NSAIDs) also provide some prevention for flushing, although recent studies have shown that it is not as effective as laropiprant. There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements.
authors.affiliation: Chicago Medical School/North Chicago Veterans Affairs, IL, USA. aditya.sood@my.rfums.org
authors.forename: Aditya
authors.initials: A
authors.lastname: Sood
authors.forename: Rohit
authors.initials: R
authors.lastname: Arora
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D009525:Niacin / Q000009:adverse effects* / Q000627:therapeutic use*; D011537:Pruritus / Q000517:prevention & control*
chemical_list: D000960:Hypolipidemic Agents; D007211:Indoles; C518174:MK-0524; D009525:Niacin; D001241:Aspirin